- Home
- HMY vs BIO Comparison
HMY vs BIO Comparison
Compare HMY & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- BIO
- Stock Information
- Founded
- HMY 1950
- BIO 1952
- Country
- HMY South Africa
- BIO United States
- Employees
- HMY N/A
- BIO N/A
- Industry
- HMY Precious Metals
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- HMY Basic Materials
- BIO Industrials
- Exchange
- HMY Nasdaq
- BIO Nasdaq
- Market Cap
- HMY 9.4B
- BIO 7.7B
- IPO Year
- HMY N/A
- BIO N/A
- Fundamental
- Price
- HMY $18.31
- BIO $297.20
- Analyst Decision
- HMY Hold
- BIO Strong Buy
- Analyst Count
- HMY 2
- BIO 4
- Target Price
- HMY $12.20
- BIO $333.50
- AVG Volume (30 Days)
- HMY 6.7M
- BIO 214.4K
- Earning Date
- HMY 01-01-0001
- BIO 10-29-2025
- Dividend Yield
- HMY 0.76%
- BIO N/A
- EPS Growth
- HMY 67.74
- BIO N/A
- EPS
- HMY 1.29
- BIO 11.49
- Revenue
- HMY $4,161,584,110.00
- BIO $2,554,200,000.00
- Revenue This Year
- HMY $23.79
- BIO $2.12
- Revenue Next Year
- HMY $1.71
- BIO $2.90
- P/E Ratio
- HMY $14.04
- BIO $25.93
- Revenue Growth
- HMY 20.39
- BIO N/A
- 52 Week Low
- HMY $7.97
- BIO $211.43
- 52 Week High
- HMY $18.94
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- HMY 67.23
- BIO 58.13
- Support Level
- HMY $16.92
- BIO $266.71
- Resistance Level
- HMY $18.92
- BIO $286.84
- Average True Range (ATR)
- HMY 0.62
- BIO 8.86
- MACD
- HMY 0.29
- BIO 2.64
- Stochastic Oscillator
- HMY 85.85
- BIO 71.98
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.